VASOPRESSIN INJECTION, USP SOLUTION

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

VASOPRESSIN

Disponível em:

FRESENIUS KABI CANADA LTD

Código ATC:

H01BA01

DCI (Denominação Comum Internacional):

VASOPRESSIN (ARGIPRESSIN)

Dosagem:

20UNIT

Forma farmacêutica:

SOLUTION

Composição:

VASOPRESSIN 20UNIT

Via de administração:

INTRAMUSCULAR

Unidades em pacote:

1ML

Tipo de prescrição:

Prescription

Área terapêutica:

PITUITARY

Resumo do produto:

Active ingredient group (AIG) number: 0106469001; AHFS:

Status de autorização:

APPROVED

Data de autorização:

1998-07-02

Características técnicas

Prescribing Information - Vasopressin Injection, USP
Page 1 of 9_ _
PRESCRIBING INFORMATION
PR
VASOPRESSIN INJECTION, USP
Vasopressin Injection
Sterile Solution
20 USP units / mL
Synthetic
For Intramuscular (IM) or Subcutaneous (SC) Injection
Antidiuretic Agent
Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8
Date of Initial Authorization:
OCT 03, 1994
Date of Revision:
MAR 28, 2022
Submission Control Number: 255357
Prescribing Information - Vasopressin Injection, USP
Page 2 of 9_ _
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
03/2022
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
03/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..................................................................................................2
TABLE OF CONTENTS
..................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................4
1
INDICATIONS
..................................................................................................................4
1.1
Pediatrics.............................................................................................................
4
1.2
Geriatrics
.............................................................................................................
4
2
CONTRAINDICATIONS......................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
....................................................................4
4
DOSAGE AND ADMINISTRATION
.......................................................................................5
4.1
Dosing Considerations
...........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
...............................................